India, Sept. 14 -- Several biotech stocks were in focus Monday, including Tyra Biosciences following a $400 million stock and warrant offering to advance its dabogratinib 3x3 strategy; Nasus Pharma after FDA clearance of its IND for intranasal epinephrine NS002; Bionano Genomics following peer-reviewed OGM study results; and Tenaya Therapeutics after TN-401 received FDA RMAT designation.
Read on.
Tyra Biosciences (TYRA) shares are surging more than 15% after the company announced the pricing of a $400 million underwritten offering of common stock and pre-funded warrants to advance its "dabogratinib 3x3" development strategy in low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer and achondroplas...